Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 3Phase 1 2Phase 2/3 1Phase 1/2 1

Status

Completed 23Terminated 10Withdrawn 2Active not recruiting 2

Sponsor Class

NIH 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Dermatologic 1

Conditions

Sarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 35Cisplatin 24fludarabine 23Radiotherapy 23Paclitaxel 21Carboplatin 20pembrolizumab 18Nivolumab 18Magnetic Resonance Spectroscopy 18Specimen Handling 17fludarabine phosphate 15Gemcitabine 15Biopsy 15Cytarabine 14Radiation 11Filgrastim 11Doxorubicin 11Docetaxel 11Dexamethasone 11Radiosurgery 10Granulocyte Colony-Stimulating Factor 10Etoposide 10Melphalan 9Ipilimumab 9venetoclax 8Rituximab 8Calcium Dobesilate 8trametinib 7ibrutinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × Celecoxib × Clear all
NCT02839694 2018-07-05

Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Neoplasms, Germ Cell and Embryonal, Sarcoma

NCT00108186 2014-10-29

Celecoxib Treatment for Lung Cancer

VA Office of Research and Development

Phase 1 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡